Liang Zhang1, Wei Ou1, Qianwen Liu1, Ning Li1, Li Liu1, Siyu Wang1. 1. Department of Thoracic Surgery, Sun Yat-sen University Cancer Center Guangzhou, Guangdong Province, China; State Key Laboratory of Oncology in South China Guangzhou, Guangdong Province, China.
Abstract
BACKGROUND: Cisplatin-based adjuvant chemotherapy provided a significant advantage in the overall survival (OS) of patients with stage II and III non-small cell lung cancer (NSCLC). However, the compliance and toxicity in cisplatin-based treatment were not always satisfactory. Pemetrexed plus carboplatin (PC) had better chemotherapy compliance and efficiency in advanced non-squamous NSCLC patients. The aim of our study was to investigate the feasibility and efficacy of PC as adjuvant chemotherapy in patients with completely resected non-squamous NSCLC. METHODS: Eighty-two eligible non-squamous NSCLC patients operated on with pathological stage II or IIIA were enrolled in this trial. Adjuvant chemotherapy was initiated between one and four weeks after surgery, and consisted of four cycles of pemetrexed (500 mg/m2) plus carboplatin (AUC = 5) every three weeks. The primary endpoint was the compliance of the regimen and the second endpoint was disease-free survival (DFS). RESULTS: Patient demographics were median age 58 years (range 32 to 78) and gender ratio 68.3% male/31.7% female. Forty-eight (58.5%) of the patients were at stage II, and the other thirty-four (41.5%) patients were at stage IIIA. Seventy patients (85.4%) received four cycles of therapy over a 12-week period. Reasons for discontinuing therapy included: patient's refusal (n = 10); severe adverse events (n = 1); and surgical complications (n = 1). The primary grade 3 to 4 adverse reaction was hematologic toxicity: neutropenia (13.4%); leucopenia (7.3%); anemia (3.7%); and thrombocytopenia (2.4%). Non-hematological adverse events were mild. No treatment related deaths were observed. Median DFS for stage II and IIIA patients were 38.0 months (95% confidence interval (CI): 28.1 to 47.9 months) and 21.0 months (95%CI: 13.7 to 28.3 months), respectively. CONCLUSION: Adjuvant PC chemotherapy was an acceptable regimen in resected non-squamous NSCLC patients.
BACKGROUND:Cisplatin-based adjuvant chemotherapy provided a significant advantage in the overall survival (OS) of patients with stage II and III non-small cell lung cancer (NSCLC). However, the compliance and toxicity in cisplatin-based treatment were not always satisfactory. Pemetrexed plus carboplatin (PC) had better chemotherapy compliance and efficiency in advanced non-squamous NSCLCpatients. The aim of our study was to investigate the feasibility and efficacy of PC as adjuvant chemotherapy in patients with completely resected non-squamous NSCLC. METHODS: Eighty-two eligible non-squamous NSCLCpatients operated on with pathological stage II or IIIA were enrolled in this trial. Adjuvant chemotherapy was initiated between one and four weeks after surgery, and consisted of four cycles of pemetrexed (500 mg/m2) plus carboplatin (AUC = 5) every three weeks. The primary endpoint was the compliance of the regimen and the second endpoint was disease-free survival (DFS). RESULTS:Patient demographics were median age 58 years (range 32 to 78) and gender ratio 68.3% male/31.7% female. Forty-eight (58.5%) of the patients were at stage II, and the other thirty-four (41.5%) patients were at stage IIIA. Seventy patients (85.4%) received four cycles of therapy over a 12-week period. Reasons for discontinuing therapy included: patient's refusal (n = 10); severe adverse events (n = 1); and surgical complications (n = 1). The primary grade 3 to 4 adverse reaction was hematologic toxicity: neutropenia (13.4%); leucopenia (7.3%); anemia (3.7%); and thrombocytopenia (2.4%). Non-hematological adverse events were mild. No treatment related deaths were observed. Median DFS for stage II and IIIA patients were 38.0 months (95% confidence interval (CI): 28.1 to 47.9 months) and 21.0 months (95%CI: 13.7 to 28.3 months), respectively. CONCLUSION: Adjuvant PC chemotherapy was an acceptable regimen in resected non-squamous NSCLCpatients.
Authors: Elizabeth M Blanchard; James Moon; Paul J Hesketh; Karen Kelly; Antoinette J Wozniak; John Crowley; David Gandara Journal: J Thorac Oncol Date: 2011-01 Impact factor: 15.609
Authors: D Waller; M D Peake; R J Stephens; N H Gower; R Milroy; M K B Parmar; R M Rudd; S G Spiro Journal: Eur J Cardiothorac Surg Date: 2004-07 Impact factor: 4.191
Authors: Eleni M Karapanagiotou; Paraskevi G Boura; George Papamichalis; Marios Konstantinou; Evangellos Sepsas; George Chamalakis; Panagiotis Simsiris; Ioannis Gkiozos; Kostas N Syrigos Journal: Anticancer Res Date: 2009-10 Impact factor: 2.480
Authors: Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier Journal: J Clin Oncol Date: 2008-05-27 Impact factor: 44.544
Authors: Andrea Ardizzoni; Luca Boni; Marcello Tiseo; Frank V Fossella; Joan H Schiller; Marianne Paesmans; Davorin Radosavljevic; Adriano Paccagnella; Petr Zatloukal; Paola Mazzanti; Donald Bisset; Rafael Rosell Journal: J Natl Cancer Inst Date: 2007-06-06 Impact factor: 13.506
Authors: Thomas E Stinchcombe; Harry D Harper; Thomas A Hensing; Dominic T Moore; Jeffery M Crane; James N Atkins; Ellen M Willard; Frank C Detterbeck; Mark A Socinski Journal: J Thorac Oncol Date: 2008-02 Impact factor: 15.609
Authors: Cheol-Kyu Park; Hyung-Joo Oh; Seung Soo Yoo; Shin Yup Lee; Sang Hoon Lee; Eun Young Kim; Sung Yong Lee; Juwhan Choi; Min Ki Lee; Mi-Hyun Kim; Tae Won Jang; Chaeuk Chung; In-Jae Oh; Young-Chul Kim Journal: Transl Lung Cancer Res Date: 2022-08